Invitrogen expects to continue its aggressive acquisition strategy through the remainder of the year, but it is possible after a string of relatively small purchases that the firm may be ready to add a "transforming" piece to its business, CEO Greg Lucier suggested during a webcast last week.

Lucier was one of several members of Invitrogen's management to address attendees of the company's 2005 investor meeting at its headquarters in Carlsbad, Calif.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

In Nature this week: a Danish reference genome, and more.